Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Open Access
- 7 April 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (3) , 668-690
Abstract
Patients with Type 2 diabetes mellitus (T2DM) frequently exhibit a distinctive cardiac phenotype known as diabetic cardiomyopathy. Cardiac complications associated with T2DM include cardiac inflammation, hypertrophy, fibrosis, and diastolic dysfunction in the early stages of the disease, which can progress to systolic dysfunction and heart failure. Effective therapeutic options for diabetic cardiomyopathy are limited and often have conflicting results. The lack of effective treatments for diabetic cardiomyopathy is due in part, to our poor understanding of the disease development and progression, as well as a lack of robust and valid preclinical human models that can accurately recapitulate the pathophysiology of the human heart. In addition to cardiomyocytes, the heart contains a heterogeneous population of non-myocytes including fibroblasts, vascular cells, autonomic neurons, and immune cells. These cardiac non-myocytes play important roles in cardiac homeostasis and disease, yet the effect of hyperglycaemia and hyperlipidaemia on these cell types is often overlooked in preclinical models of diabetic cardiomyopathy. The advent of human-induced pluripotent stem cells provides a new paradigm in which to model diabetic cardiomyopathy as they can be differentiated into all cell types in the human heart. This review will discuss the roles of cardiac non-myocytes and their dynamic intercellular interactions in the pathogenesis of diabetic cardiomyopathy. We will also discuss the use of sodium-glucose cotransporter 2 inhibitors as a therapy for diabetic cardiomyopathy and their known impacts on non-myocytes. These developments will no doubt facilitate the discovery of novel treatment targets for preventing the onset and progression of diabetic cardiomyopathy.Keywords
Funding Information
- St Vincent’s Hospital (Melbourne) Research Endowment Fund
- Stafford Fox Medical Research Foundation
- St Vincent’s Institute Rising Star Award
- Victorian Government (Australia) Operational Infrastructure
- St Vincent’s Institute of Medical Research
- Duke-NUS Signature Research Programme
- Ministry of Health, Singapore Ministry of Health’s National Medical Research Council (NMRC/CSA-SI/0011/2017, CGAug16M006, NMRC/CGAug16C006)
This publication has 381 references indexed in Scilit:
- Cardiac Fibroblast-Dependent Extracellular Matrix Accumulation Is Associated with Diastolic Stiffness in Type 2 DiabetesPLOS ONE, 2013
- Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapyNature Reviews Cardiology, 2012
- Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1Proceedings of the National Academy of Sciences, 2012
- Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: Evidence of a sex difference? The Western New York experienceNutrition, Metabolism and Cardiovascular Diseases, 2011
- Evaluation of specific metabolic rates of major organs and tissues: Comparison between men and womenAmerican Journal of Human Biology, 2010
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family membersDiabetes Therapy, 2010
- Cardiac 12/15 lipoxygenase–induced inflammation is involved in heart failureJournal of Experimental Medicine, 2009
- WISP1, a Pro-mitogenic, Pro-survival Factor, Mediates Tumor Necrosis Factor-α (TNF-α)-stimulated Cardiac Fibroblast Proliferation but Inhibits TNF-α-induced Cardiomyocyte DeathJournal of Biological Chemistry, 2009
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetesNature Genetics, 2006